Outcomes with DA-EPOCH-R in the Treatment of Aggressive B Cell Lymphoma

Dose-adjusted (DA)-EPOCH-R has been utilized in efforts to improve upon R-CHOP as the standard treatment of diffuse large B cell lymphoma (DLBCL). Front-line R-CHOP vs. DA-EPOCH-R in a randomized controlled trial resulted in no difference in clinical outcomes (CALGB/Alliance 50303, ASH 2016). However, DA-EPOCH-R may still be considered in high grade B cell lymphoma (HGBCL), MYC aberrant/ “double hit lymphoma” (DHL), primary mediastinal B cell lymphoma (PMBCL), B cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma (also known as gray zone lymphoma (GZL)), and HIV-associated lymphoma.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Craig Boddy, Carlos Galvez, Barbara Pro, Angela Fought, Leo Gordon, Jane Winter, Shuo Ma, Reem Karmali, Jason Kaplan Source Type: research